Dr. Shah on Daratumumab-Based Regimens in Frontline Multiple Myeloma
January 28th 2020Nina Shah, MD, associate professor of medicine at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses daratumumab (Darzalex)-based regimens in the frontline treatment of patients with multiple myeloma.
Dr. Fakhri on the Use of PI3K Inhibitors in Relapsed/Refractory CLL
January 24th 2020Bita Fakhri, MD, MPH, assistant professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of PI3K inhibitors in relapsed/refractory chronic lymphocytic leukemia (CLL).
Dr. Martin on Treating First Relapse in Multiple Myeloma
January 14th 2020Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California, San Francisco, and co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses the management of first relapse in patients with multiple myeloma.
Dr. Dunavin on Treatment Considerations in Myelofibrosis
January 10th 2020Neil Dunavin, MD, MS, assistant professor of medicine, School of Medicine, University of California, San Francisco (UCSF), UCSF Helen Diller Family Comprehensive Cancer Center, discusses treatment considerations in myelofibrosis.